AgingResearch.News

TrialEarly phase 1Recruiting

Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease (Senolytics)

MC230715 Pilot Study of the Mechanistic Feedback From CNS Tumors With Latent Residual Disease to Guide Individualized Therapies

Sponsor
Mayo Clinic (Academic or other)
Enrolment
30 planned
Conditions
Glioma
Interventions
Biospecimen Collection; Dasatinib; Fisetin; Magnetic Resonance Imaging; Patient Observation; Positron Emission Tomography; Quercetin; Temozolomide; Topoisomerase-1 Inhibitor LMP744; Single Agent Therapy
Ages
adults, older adults
Registry
NCT07025226

From the registry

This early phase I trial tests the safety, side effects and how well medication combinations of dasatinib, quercetin, fisetin, temozolomide, LMP744, and autologous tumor lysate particle only (TLPO) vaccine work in treating patients with glioma for which the patient has received treatment in the past (previously treated) and for tumor cells that remain after attempts to treat the tumor have been made (residual disease). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply, which may help keep tumor cells from growing. Quercetin and fisetin are compounds found in plants. They have antioxidant and anti-inflammatory properties and help remove senescent cells, older or damaged cells that have stopped dividing but don't die off as they should and build up in tissues over time. Senescent cells may cause inflammation or damage to nearby healthy cells. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA)…

Primary outcomes

  • Completion of 3 cycles
  • Turnaround time for scan and marker data
Full record on ClinicalTrials.gov